CrestX
Early buildGraded evidence records for clinical partnering
CrestX turns a sponsor’s scattered study and program evidence into a single graded record, then puts a curated slice of it in front of partners, licensees and investors through permissioned data rooms.
- Product line
- TraceX + CrestX
- Sectors
- Health & life sciences, Research commercialisation & technology transfer, Agritech & animal health
- Independent timestamping
- Not implemented — not claimed
- Open to check
- 2 public surfaces
What it is for
Partnering, licensing and investment conversations in life sciences run on asserted capability — decks, CVs and publication lists — so the counterparty has to take a sponsor’s word for how well each claim is actually backed. Diligence stretches into weeks of document chasing, and well-evidenced programs lose ground to better-presented ones.
- Biotech and life-science sponsors preparing for partnering, licensing or a raise
- Universities, research institutes and technology-transfer offices commercialising a program
- Clinics, trial sites and contract research groups whose work must count on the other side of the table
- Licensing partners, corporate development teams and specialist investors running diligence
What you get
Every claim shows its backing
Each finding sits on a visible provenance ladder — from third-party preclinical work down to concept — so a reader can tell in seconds which claims are supported and which are still an idea. Evidence is graded by the strength of its source; it is never presented as proof that a product works.
Diligence in hours, not weeks
A partner opens one curated room instead of chasing attachments across inboxes. What they can see is decided before they arrive, so the first meeting starts from the evidence rather than from a document request list.
A record a reader can trust has not shifted
The workspace shows on screen whether each item is unchanged since it was entered and whether the history has only ever been added to. Corrections appear as recorded revisions with their own date, never as silent overwrites.
Share exactly the slice you choose
An admin picks which programs go into a room and the minimum evidence grade a partner may see, invites them on a single-use link, and can close the room instantly. Anything below the floor is simply not served.
One portfolio view before the counterparty has it
Programs roll up into a workspace-level strength summary, so a leadership team can see where the evidence is thin and fix it before a partner or investor finds it.
What you can check for yourself
Provision your own workspace from the public front door and read the provenance ladder on seeded programs.
Run the on-screen integrity check over the workspace’s own activity history.
CrestX keeps a tamper-evident record. Independent third-party timestamping is not implemented here, and we do not claim it.
What a demonstration shows
- Self-serve workspace provisioning — an organisation gets its own isolated tenant without waiting on a sales cycle, with roles and data-handling terms set before any evidence is loaded
- Evidence workspace: lead programs and their findings, each carrying a visible provenance grade
- Program detail page with a transparent strength readout and the program’s provenance history
- Workspace activity history with an on-screen integrity verdict on the record as a whole
- Partner data-room builder — choose the programs, set the minimum evidence grade, open or close the room
- Partner reviewer view — the curated, graded slice and nothing else, bound to the one room
- Single-use invite links for team members and for external partner reviewers
Built on
- Cloud-hosted, server-rendered web application
- Multi-tenant with per-organisation data isolation
- Role-based access control, with session-bound external reviewer access
- Relational system of record (PostgreSQL-portable)
- Security posture documented and reviewed with the customer before a trial tenancy is provisioned
- Your data, exportable
Categories, not construction. A technical deep-dive is available under a mutual NDA.
Where this actually is
A working prototype covering the core loop. Parts of the product are designed and not yet built; we say which.
A working prototype, not yet in production. A multi-tenant web application runs today with self-serve signup, the graded evidence register, program and portfolio strength readouts, an on-screen record-integrity check, and permissioned partner rooms with single-use reviewer invites. Independent third-party verification of the underlying science, connectors to study and trial-management systems, exports, an API and billing are designed but not built. There is no production deployment, no certification and no live customer; demonstrations run on seeded data. CrestX grades how well a claim is evidenced — it does not assess whether a therapy or product works, and it is not a regulatory submission.
CrestX grades how well a claim is evidenced. It does not assess whether a therapy or product works, it is not a regulatory submission, and nothing in it constitutes clinical or regulatory advice.
Why this travels across the two markets
Cross-border partnering stalls because neither side can quickly read the other’s evidence. Vietnamese institutes, universities and sponsors seeking Australian partners — and Australian sponsors seeking Vietnamese trial sites, laboratories or manufacturing — both need a legible, graded record before commercial terms are worth discussing. CrestX is a working prototype seeking its first pilot workspaces on either side, plus university and research-organisation collaboration on the evidence-grading ladder itself.